Spyre Therapeutics SYRE
NASDAQ SYRE
$91.28 +1.35 (+1.50%)
As of: Oct 2, 2026 · 3:06 PM EDT

Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2015 - 2024)

Updated

Spyre Therapeutics (SYRE) posted Preferred Stock Liabilities of $253.41 million for Q1 2024, up 199.7% from the prior quarter.

Analysis

Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2015 - 2024) Analysis & Trends

At the end of FY2023, Spyre Therapeutics' Preferred Stock Liabilities came in at $84.56 million.

  • Quarterly Preferred Stock Liabilities has run from a low of $84.56 million in Q4 2023 to a high of $387.11 million in Q3 2023 over five years.
  • According to Business Quant data, Preferred Stock Liabilities for the three prior quarters was $84.56 million (Q4 2023), $387.11 million (Q3 2023) and $197.32 million (Q2 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Spyre Therapeutics 7.84 Bn 7.84 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 253.41 Mn
Dec 31, 2023 84.56 Mn
Sep 30, 2023 387.11 Mn
Jun 30, 2023 197.32 Mn
Mar 31, 2016 58.31 Mn
Dec 31, 2015 58.31 Mn
API Access

Spyre Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=SYRE&period=max&api_key=YOUR_API_KEY